Unveiling the functional roles of patient‐derived tumour organoids in assessing the tumour microenvironment and immunotherapy

Abstract

Abstract Recent studies have established the pivotal roles of patient‐derived tumour organoids (PDTOs), innovative three‐dimensional (3D) culture systems, in various biological and medical applications. PDTOs, as promising tools, have been established and extensively used for drug screening, prediction of immune response and assessment of immunotherapeutic effectiveness in various cancer types, including glioma, ovarian cancer and so on. The overarching goal is to facilitate the translation of new therapeutic modalities to guide personalised immunotherapy. Notably, there has been a recent surge of interest in the co‐culture of PDTOs with immune cells to investigate the dynamic interactions between tumour cells and immune microenvironment. A comprehensive and in‐depth investigation is necessary to enhance our understanding of PDTOs as promising testing platforms for cancer immunotherapy. This review mainly focuses on the latest updates on the applications and challenges of PDTO‐based methods in anti‐cancer immune responses. We strive to provide a comprehensive understanding of the potential and prospects of PDTO‐based technologies as next‐generation strategies for advancing immunotherapy approaches.

Keywords

• cancer
• immunotherapy
• organoids
• tumour microenvironment